155 related articles for article (PubMed ID: 30623356)
1. Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study.
Tobinai K; Uchida T; Fukuhara N; Nishikawa T
Int J Hematol; 2019 Mar; 109(3):366-368. PubMed ID: 30623356
[No Abstract] [Full Text] [Related]
2. Phase I study of ibrutinib in Japanese patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma.
Shibayama H; Teshima T; Choi I; Hatake K; Sekiguchi N; Yoshinari N
J Clin Exp Hematop; 2019; 59(4):179-186. PubMed ID: 31866619
[TBL] [Abstract][Full Text] [Related]
3. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
[TBL] [Abstract][Full Text] [Related]
4. Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.
Maruyama D; Nagai H; Fukuhara N; Kitano T; Ishikawa T; Nishikawa T
J Clin Exp Hematop; 2019; 59(2):98-100. PubMed ID: 31257351
[No Abstract] [Full Text] [Related]
5. Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly.
Ruella M; Soubeyran P
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):432-436. PubMed ID: 27913512
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies.
Tobinai K; Ogura M; Ishizawa K; Suzuki T; Munakata W; Uchida T; Aoki T; Morishita T; Ushijima Y; Takahara S
Int J Hematol; 2016 Jan; 103(1):86-94. PubMed ID: 26588924
[TBL] [Abstract][Full Text] [Related]
7. Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
Titus-Rains KS; Brown JN; Hammond JM
J Oncol Pharm Pract; 2018 Oct; 24(7):544-549. PubMed ID: 28714377
[TBL] [Abstract][Full Text] [Related]
8. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
Lee CS; Rattu MA; Kim SS
J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
[TBL] [Abstract][Full Text] [Related]
9. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
10. Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.
Siddiqi T; Coutre S; McKinney M; Barr PM; Rogers K; Mokatrin A; Valentino R; Szoke A; Deshpande S; Zhu A; Arango-Hisijara I; Osei-Bonsu K; Wang M; O'Brien S
Leuk Lymphoma; 2022 Jul; 63(7):1580-1588. PubMed ID: 35227147
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.
McMullen JR; Boey EJ; Ooi JY; Seymour JF; Keating MJ; Tam CS
Blood; 2014 Dec; 124(25):3829-30. PubMed ID: 25498454
[No Abstract] [Full Text] [Related]
12. [Ibrutinib: A new drug of B-cell malignancies].
Thieblemont C
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S85-90. PubMed ID: 26118882
[TBL] [Abstract][Full Text] [Related]
13. Infection with ibrutinib in patients with chronic lymphocytic leukemia: How strong is the association?
Ball S; Vutthikraivit W; Maiti A; Short NJ
Eur J Haematol; 2018 Sep; 101(3):418-420. PubMed ID: 29791043
[No Abstract] [Full Text] [Related]
14. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation.
Kamel S; Horton L; Ysebaert L; Levade M; Burbury K; Tan S; Cole-Sinclair M; Reynolds J; Filshie R; Schischka S; Khot A; Sandhu S; Keating MJ; Nandurkar H; Tam CS
Leukemia; 2015 Apr; 29(4):783-7. PubMed ID: 25138588
[TBL] [Abstract][Full Text] [Related]
15. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
O'Brien S; Hillmen P; Coutre S; Barr PM; Fraser G; Tedeschi A; Burger JA; Dilhuydy MS; Hess G; Moreno C; Cramer P; Liu E; Chang S; Vermeulen J; Styles L; Howes A; James DF; Patel K; Graef T; Valentino R
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):648-657.e15. PubMed ID: 30061088
[TBL] [Abstract][Full Text] [Related]
16. The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
Hallek M; Kay NE; Osterborg A; Chanan-Khan AA; Mahler M; Salman M; Wan Y; Sun S; Zhuang SH; Howes A
Future Oncol; 2015; 11(1):51-9. PubMed ID: 24901734
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.
Rule S; Jurczak W; Jerkeman M; Rusconi C; Trneny M; Offner F; Caballero D; Joao C; Witzens-Harig M; Hess G; Bence-Bruckler I; Cho SG; Thieblemont C; Zhou W; Henninger T; Goldberg J; Vermeulen J; Dreyling M
Leukemia; 2018 Aug; 32(8):1799-1803. PubMed ID: 29572505
[No Abstract] [Full Text] [Related]
18. Adverse drug events associated with ibrutinib for the treatment of elderly patients with chronic lymphocytic leukemia: A systematic review and meta-analysis of randomized trials.
Zhou Y; Lu H; Yang M; Xu C
Medicine (Baltimore); 2019 Aug; 98(33):e16915. PubMed ID: 31415440
[TBL] [Abstract][Full Text] [Related]
19. How should we use ibrutinib in patients with mantle cell lymphoma?
Jerkeman M
Br J Haematol; 2021 May; 193(3):445-446. PubMed ID: 33694156
[No Abstract] [Full Text] [Related]
20. Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia.
Amin NA; Balasubramanian S; Saiya-Cork K; Shedden K; Hu N; Malek SN
Clin Cancer Res; 2017 Feb; 23(4):1049-1059. PubMed ID: 27535981
[No Abstract] [Full Text] [Related]
[Next] [New Search]
